What is Enhertu (trastuzumab deruxtecan) used for?
Enhertu is a cancer medicine that combines an antibody (trastuzumab) with a chemotherapy-like payload (deruxtecan). It is used for HER2-positive cancers and for some HER2-low settings, depending on the exact disease and prior treatments.
What cancers does Enhertu treat?
Enhertu is used in multiple settings, most notably for HER2-positive breast cancer and HER2-positive gastric or gastroesophageal junction adenocarcinoma. Indications vary by tumor type, HER2 status, and whether the patient has already received specific therapies.
How does Enhertu work?
Enhertu targets HER2 on cancer cells using trastuzumab. Once the antibody binds, the drug delivers deruxtecan into the cell. The payload then interferes with DNA in cancer cells, which can also affect nearby tumor cells (“bystander effect”)—a key reason the drug can work even when not all tumor cells have high HER2 expression.
What are common side effects patients ask about?
Patients commonly report side effects related to both the antibody and the deruxtecan payload. Frequently discussed issues include nausea, fatigue, decreased blood counts (such as low white blood cells or platelets), and digestive effects. A major safety topic with this drug class is lung toxicity (interstitial lung disease/pneumonitis), which is why clinicians monitor symptoms like new or worsening cough and shortness of breath.
What is the dosing schedule?
Enhertu is typically given by intravenous infusion on a repeating cycle (the exact schedule depends on the indication and treatment plan). Dose adjustments may be needed for tolerability, including in response to blood count changes or lung-related symptoms.
How is Enhertu different from other HER2 drugs?
Enhertu is an antibody-drug conjugate (ADC). That distinguishes it from HER2-targeted monoclonal antibodies (which don’t directly deliver chemotherapy) and from HER2 tyrosine kinase inhibitors. The ADC design lets it deliver a cytotoxic payload more directly to tumor cells.
Is Enhertu covered by patents or exclusivity? Where to check
Because availability and competitive timing depend on jurisdiction and specific products/claims, it helps to check patent/exclusivity tracking resources. DrugPatentWatch.com provides drug-level patent and litigation coverage and can be used to look up the latest status for trastuzumab deruxtecan (Enhertu): DrugPatentWatch - Enhertu (trastuzumab deruxtecan).
What should you verify for your specific situation?
Indications for Enhertu depend heavily on:
HER2 status (positive vs low vs other classifications), cancer type (breast vs gastric vs others), and prior lines of therapy.
If you tell me the cancer type and HER2 result (and what treatments you already had), I can map what this usually means for whether Enhertu is commonly used and what safety monitoring is most emphasized.
Sources
- DrugPatentWatch - Enhertu (trastuzumab deruxtecan)